Literature DB >> 1903039

The potential of biotechnology to improve the quality of life of patients with renal failure.

W E Bloembergen1, A Laupacis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1903039     DOI： 10.2165/00002018-199106010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  47 in total

Review 1.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

2.  Is erythropoietin effective for impotence in dialysis patients?

Authors:  A Imagawa; Y Kawanishi; A Numata
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  The use of monoclonal antibodies in fine needle aspiration biopsy of the renal transplant.

Authors:  J H Helderman
Journal:  Am J Kidney Dis       Date:  1988-02       Impact factor: 8.860

4.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

5.  Purification of human erythropoietin.

Authors:  T Miyake; C K Kung; E Goldwasser
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

6.  Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.

Authors:  C Bombardier; J Ware; I J Russell; M Larson; A Chalmers; J L Read
Journal:  Am J Med       Date:  1986-10       Impact factor: 4.965

7.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

8.  How should we measure function in patients with chronic heart and lung disease?

Authors:  G H Guyatt; P J Thompson; L B Berman; M J Sullivan; M Townsend; N L Jones; S O Pugsley
Journal:  J Chronic Dis       Date:  1985

9.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

Authors:  J W Eschbach; M H Abdulhadi; J K Browne; B G Delano; M R Downing; J C Egrie; R W Evans; E A Friedman; S E Graber; N R Haley
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

10.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.